Categories: AnalystsCannabis

Buy cannabis stock CannTrust Holdings for a double, Echelon says

Having just announced its pending graduation to the TSX, CannTrust Holdings (CannTrust Holdings Stock Quote, Chart: CSE:TRST) deserves a price bump, says analyst Russell Stanley of Echelon Wealth Partners, who gives TRST a “Speculative Buy” with a projected return of 102 per cent.

Yesterday, Vaughan, Ontario-based cannabis producer CannTrust Holdings announced that it has received conditional approval from the Toronto Stock Exchange to list its shares. Final approval will be subject to CannTrust meeting TSX’s requirements by a TSX-imposed May 21 deadline, including divesting itself of interests in the United States, where cannabis remains federally a Schedule 1 narcotic. CannTrust has stated it will therefore be assigning its interest in the joint venture company Cannabis Coffee & Tea Pod Company to an affiliated company.

CannTrust Holdings stock move to TSX could be a benefit

The move from the Canadian Stock Exchange to the TSX will broaden TRST’s audience, says Stanley.

“While the CSE has gained prominence in part because of the number of cannabis companies listed there, we understand that some institutional investors require a company to have a TSX or TSXV- listing at a minimum. We therefore view this as a positive step for TRST,” the analyst said in an update to clients on Thursday.

“We are leaving our estimates unchanged at this time, but believe the TSX listing warrants a higher valuation multiple,” says the analyst. “TRST currently trades at just under 8x EV/2019E EBITDA based on our estimates vs. the adjusted average for the broad peer group of just under 16x (based on consensus estimates).”

Stanley has upped TRST’s estimated enterprise value/EBITDA multiple from 14.5x to 16.0x EV/2019E EBITDA and increased his 12-month target price from $16.75 to $18.50, representing a 102 per cent return at time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: trst
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago